Aikaterini Dimitriou

Eculizumab improves fatigue in refractory generalized myasthenia gravis

K. Patra, P. van Damme, M. Benatar, 2019, Quality of Life Research.

Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study.

G. L. Masson, W. Löscher, P. Vermersch, 2017, The Lancet. Neurology.

Proinflammatory cytokines in serum and cerebrospinal fluid of CIDP patients

A. Rombos, I. Evdokimidis, A. Kyrozis, 2012, Neurological research.

Long-term efficacy and safety of eculizumab in Japanese patients with generalized myasthenia gravis: A subgroup analysis of the REGAIN open-label extension study

P. van Damme, M. Benatar, F. Piehl, 2019, Journal of the Neurological Sciences.

COVID-19 Burden in Long-Term Care Facilities in the Omicron Era: Public Health Action Not Yet Redundant

D. Paraskevis, K. Mellou, K. Tryfinopoulou, 2023, Viruses.

‘Minimal symptom expression’ in patients with acetylcholine receptor antibody-positive refractory generalized myasthenia gravis treated with eculizumab

P. van Damme, M. Benatar, F. Piehl, 2020, Journal of Neurology.

Oral Manifestations and Dental Treatment of Patients with Klinefelter Syndrome: Report of Two Cases

A. Giannopoulou, Aikaterini Dimitriou, Kalliopi Konstantopoulou, 2022 .